Calcitonin gene-related peptide-targeted monoclonal antibodies (CGRP mAbs) are
increasingly being used as preventive treatments for migraine. Their effectiveness and …

Background Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its
receptor (anti-CGRP (-R) mAbs) and small-molecule CGRP receptor antagonists (gepants) …

Background and objectives The identification of predictors of response to antiCGRP mAbs
could favor tailored therapies and personalized treatment plans. This study is aimed at …

Background Fremanezumab has demonstrated to be effective, safe, and tolerated in the
prevention of episodic or chronic migraine (CM) in randomized, placebo-controlled trials …

Background Criteria, including clinical features and effective outcomes, for access and
persistence of novel but costly treatments may vary between countries, thus affecting the …

Background Clinical trials have shown that erenumab is effective and well-tolerated for the
preventive treatment of chronic migraine. To extend the results from clinical trials, we …

Background Clinical trials and real-world studies revealed a spectrum of response to CGRP
(-receptor) monoclonal antibodies (mAbs) in migraine prophylaxis, ranging from no effect at …

Abstract Background and Purpose To evaluate the 1‐year effectiveness and tolerability of
galcanezumab in real life and the prognostic indicators of persistent response. Methods …

Background Monoclonal antibodies anti-calcitonin gene-related peptide (mAbs anti-CGRP)
pathway are effective and safe on migraine prevention. However, some drug agencies …

Objective: To perform a systematic review of real-world outcomes for anti-CGRP-mAbs.
Methods: Following the PRISMA guidelines, we searched PubMed for real-world data of …